| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,885,914 | -4,540,621 | -4,856,395 | -10,523,246 |
| Net loss | -5,885,914 | -4,540,621 | -4,856,395 | -10,523,246 |
| Depreciation expense | - | - | 215,069 | - |
| Stock-based compensation | 1,617,455 | 259,666 | 348,116 | 488,274 |
| Write off of deferred offering costs | - | - | 500,000 | - |
| Amortization of right-to-use operating lease asset | 214,443 | 208,832 | 203,412 | 391,417 |
| Gain from settlement of liabilities with vendors | - | - | 0 | - |
| Write off of deferred offering costs | - | 105,419 | 500,000 | - |
| Gain from settlement of liabilities with vendors | - | 0 | 0 | - |
| Stock-based inducement expense-Successor | - | - | 0 | 863,550 |
| Amortization of debt discount | 136,765 | 0 | 0 | - |
| Foreign currency transaction gain included in other income (expenses) | 173 | 0 | 248 | - |
| Derivative expense | -896,722 | - | - | - |
| Prepaid expenses and other current assets | -354,991 | 540,073 | 87,935 | 169,143 |
| Accounts payable | 105,955 | 503,557 | 864,545 | 561,901 |
| Accrued liabilities | 136,977 | 23,120 | -24,369 | -404,289 |
| Insurance financing liability | -142,950 | 338,279 | - | - |
| Operating lease liability | -237,527 | -231,916 | -221,595 | -422,881 |
| Gain on revaluation of earnout liability | -19,500 | - | - | - |
| Depreciation expense | 61,699 | 67,304 | 69,354 | 145,715 |
| Amortization of debt discount | 136,765 | - | - | - |
| Payment of offering costs | - | 105,419 | - | - |
| Gain on revaluation of earnout liability | -19,500 | - | - | - |
| Proceeds from issuance of series a preferred stock, net of issuance costs | - | 0 | 0 | 0 |
| Inducement expense | 0 | - | - | - |
| Advances from shareholder | - | 0 | 0 | 0 |
| Gain on revaluation of earnout and derivative liabilities | - | 0 | 0 | - |
| Inducement expense | 0 | 863,550 | - | - |
| Payment of sponsor loans | - | 0 | 0 | 0 |
| Net cash used in operating activities | -2,761,057 | -3,806,433 | -3,205,115 | -9,068,702 |
| Proceeds from short term borrowings, net | - | 0 | 0 | 0 |
| Payments for short term borrowings | - | 0 | 0 | 0 |
| Proceeds received from sale of series b preferred stock | - | - | 0 | - |
| Proceeds received from sale of series c preferred stock, net of issuance costs of 434,428 | - | - | -2,240,180 | 2,240,180 |
| Proceeds from sale of equity securities | - | 0 | 500,000 | - |
| Proceeds from share purchases under eloc, net of issuance costs | 456,166 | 5,155,645 | - | - |
| Proceeds received from sale of series b preferred stock | - | - | - | 0 |
| Net cash provided by investing activities | - | 0 | 500,000 | - |
| Proceeds from convertible notes, net | 1,500,000 | - | - | - |
| Proceeds from exercise of series a preferred warrants | 0 | 0 | 0 | 500,000 |
| Proceeds from share purchases and collection of stock subscription receivables under eloc, net of issuance costs | - | - | 1,278,217 | 2,425,906 |
| Proceeds received from sale of series d preferred stock, net of issuance costs | - | 2,560,981 | - | - |
| Proceeds received from sale of series d preferred stock | - | - | 2,560,981 | - |
| Proceeds received from sale of series e preferred stock, net of issuance costs | - | 1,926,133 | - | - |
| Proceeds from collection of stock subscriptions receivable | 0 | - | - | - |
| Proceeds received from sale of common stock and warrants, net of issuance costs | 0 | 0 | 0 | 588,000 |
| Proceeds received from sale of pre-funded warrants, net of issuance costs | 0 | 0 | 0 | 3,685,027 |
| Payment of deferred offering costs | - | - | 174,505 | - |
| Proceeds received from sale of series b preferred stock, net of issuance costs | - | 0 | - | - |
| Proceeds from exercise of pre-funded warrants | 0 | 0 | 0 | 203 |
| Proceeds received from sale of series c preferred stock, net of issuance costs | - | 0 | - | - |
| Cash redemption of series c preferred stock | 0 | 0 | 0 | 395,000 |
| Net cash provided by financing activities | 1,956,166 | 3,446,741 | 1,424,513 | 9,044,316 |
| Net (decrease) increase in cash, restricted cash and cash equivalents | -804,891 | -359,692 | -1,280,602 | -24,386 |
| Cash, restricted cash and cash equivalents at beginning of period | 1,662,380 | 2,022,072 | 3,327,060 | - |
| Cash, restricted cash and cash equivalents at end of period | 857,489 | 1,662,380 | 2,022,072 | - |
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)